HomeComparePHAS vs ADC

PHAS vs ADC: Dividend Comparison 2026

PHAS yields 2853.07% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHAS wins by $281872346866.86M in total portfolio value
10 years
PHAS
PHAS
● Live price
2853.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281872346867.04M
Annual income
$263,691,193,706,389,300.00
Full PHAS calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — PHAS vs ADC

📍 PHAS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHAS + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHAS pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHAS
Annual income on $10K today (after 15% tax)
$242,510.70/yr
After 10yr DRIP, annual income (after tax)
$224,137,514,650,430,900.00/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, PHAS beats the other by $224,137,514,650,362,240.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHAS + ADC for your $10,000?

PHAS: 50%ADC: 50%
100% ADC50/50100% PHAS
Portfolio after 10yr
$140936173433.61M
Annual income
$131,845,596,853,235,060.00/yr
Blended yield
93.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

PHAS
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHAS buys
0
ADC buys
0
No recent congressional trades found for PHAS or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASADC
Forward yield2853.07%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$281872346867.04M$178.9K
Annual income after 10y$263,691,193,706,389,300.00$80,797.29
Total dividends collected$280611873155.80M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: PHAS vs ADC ($10,000, DRIP)

YearPHAS PortfolioPHAS Income/yrADC PortfolioADC Income/yrGap
1← crossover$296,007$285,306.70$10,990$580.36+$285.0KPHAS
2$8,209,503$7,892,775.47$12,301$860.26+$8.20MPHAS
3$213,363,270$204,579,102.60$14,104$1,298.62+$213.35MPHAS
4$5,197,428,076$4,969,129,376.72$16,691$2,008.16+$5197.41MPHAS
5$118,688,009,645$113,126,761,603.35$20,580$3,205.09+$118687.99MPHAS
6$2,541,344,545,416$2,414,348,375,096.37$26,754$5,330.02+$2541344.52MPHAS
7$51,033,223,710,004$48,313,985,046,408.66$37,196$9,345.14+$51033223.67MPHAS
8$961,336,701,807,468$906,731,152,437,763.20$56,244$17,523.09+$961336701.75MPHAS
9$16,991,731,925,840,448$15,963,101,654,906,456.00$94,286$35,736.21+$16991731925.75MPHAS
10$281,872,346,867,038,600$263,691,193,706,389,300.00$178,949$80,797.29+$281872346866.86MPHAS

PHAS vs ADC: Complete Analysis 2026

PHASStock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHAS Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this PHAS vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHAS vs SCHDPHAS vs JEPIPHAS vs OPHAS vs KOPHAS vs MAINPHAS vs NNNPHAS vs EPRTPHAS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.